Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs CGEM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEM Captures Overall Composite Edge (41.0 SELL vs 48.4 HOLD), While EDIT Leads 4–2 on Growth & Valuation Pillars

CGEM Overall Winner 6-Pillar Tally: EDIT 4 – 2 CGEM Matrix Metrics: EDIT 3 – 7 CGEM

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (41.0/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus CGEM at $9.72 (6.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile CGEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs CGEM
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61
CGEM NASDAQ Head-to-Head Winner
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.56β · 104% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $13.21 · SMA50: $15.62

6-Pillar Scorecard Institutional Category Breakdown (EDIT 4 – 2 CGEM)

Columns: Metric · EDIT · CGEM
1. Valuation Multiples CGEM
Forward P/E N/M 6.7x
Trailing P/E N/M 6.7x
PEG Ratio N/M N/M
EV / Revenue 5.2x N/M
2. Growth & Scale EDIT
Revenue Growth (YoY) +37.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M N/A
Market Cap $336.5M $653.8M
3. Profitability & Quality CGEM
Gross Margin -73.3% N/A
Operating Margin -167.0% 0.0%
Net Profit Margin -144.9% 0.0%
Return on Equity (ROE) -147.4% -50.3%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$110M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $79M Net Cash $4.33 Book/Sh · -50.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 95.8% (38th %ile) 124.5% (9th %ile)
Put/Call OI Skew 0.29x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (3) vs CGEM (7)
Institutional Metric EDIT CGEM Criterion Row Edge
Market Capitalization
Scale
$336.5M $653.8M Larger Scale CGEM
Trailing P/E Ratio
Valuation
N/M 6.7x Lower Multiple CGEM
Forward P/E Ratio
Valuation
N/M 6.7x Lower Multiple CGEM
Revenue Growth (YoY)
Growth
+37.4% +0.0% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-167.0% 0.0% Higher Margin CGEM
Net Profit Margin
Profitability
-144.9% 0.0% Higher Margin CGEM
Return on Equity (ROE)
Capital Efficiency
-147.4% -50.3% Higher ROE CGEM
52-Week Range Position
Momentum
11% ($2–$4) 12% ($8–$23) Stronger Trend CGEM
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 1.56β · 104% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$50M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) N/A ($4.33 Book/Sh · -50.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EDIT +5.89 pp
EDIT: -18.94% · CGEM: -24.83%
3M Horizon EDIT +19.51 pp
EDIT: -33.85% · CGEM: -53.36%
6M Horizon EDIT +9.93 pp
EDIT: -24.7% · CGEM: -34.63%
1Y Horizon CGEM +42.53 pp
EDIT: -25.0% · CGEM: +17.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EDIT vs CGEM. Trailing 12-month operating profitability (EDIT -167.0% vs CGEM 0.0%) and valuation multiples (EDIT N/M vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

EDIT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50M
Gross Margin-73.3%
Op. Margin-167.0%
ROE / Fwd P/E-147.4% · N/M
CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-50.3% · 6.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $653.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs CGEM Key Questions & Quantitative Answers

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (41.0/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus CGEM at $9.72 (6.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile CGEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with CGEM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EDIT generates $50M in USD-normalized revenue versus N/A for CGEM. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGEM.

CGEM screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus CGEM (-50.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.